[ Why we're building Robo ]
The next advantage in pharma is not more data.
It is what companies do with it.
The number and diversity of drugs in development are skyrocketing, and pharmaceutical companies need to understand how the world is changing to make fast decisions and stay competitive.
Yet the way organizations research and evaluate drug programs hasn't fundamentally changed.
Teams scramble to piece together information from unreliable databases, internal documents, and countless other sources. Experts have limited time, so much is missed. Valuable knowledge is created in spreadsheets and presentations, but it stays scattered across the organization.
We believe there is a fundamentally better way.
And that's why we're building Robo.
[ What we believe ]
Frontier technology in service of humans.
Better coverage, better decisions.
Pharma teams should be able to explore and compare far more widely and deeply than they can today. This is fundamental to making better decisions.
AI does the work. People make the call.
Agents can search, research, and evaluate in a way humans cannot. But expertise and context come from people, and the decisions should stay with them.
Knowledge should compound.
Every drug you evaluate creates valuable knowledge. That work should be preserved, connected, and available to inform future decisions.
More than a system of record.
The next generation of enterprise software will combine the work itself with the institutional knowledge it creates.
[ Our team ]
Built by scientists and AI engineers.
We started in research labs at Johns Hopkins and UCSF before moving into building software for scientists.
Our experience spans scientific research, product development, and technology companies serving the life sciences.
We started Robo because we believe advances in AI make it possible to fundamentally improve pharma's most important job: bringing more and better drugs to people who need them.
[ Our advisors ]
Guided by people who know the work.
We're advised by experienced leaders in pharmaceutical business development, Search & Evaluation, and external innovation.
Their experience helps us build around the scientific rigor, commercial judgment, and real-world processes of the teams we serve.
Kaan Certel, PhD
Former Global Head of Oncology External Innovation at Sanofi (2017–2023).
Neela Patel, PhD
Chief Business Officer at Bonum Therapeutics. Former Director of Search & Evaluation at AbbVie. More than 20 deals executed.
Haresh Mirchandani, PhD
Former Vice President, Business Development at Johnson & Johnson.
Carlos N. Velez, PhD
Managing Partner at Lacerta Bio. CEO of Connexin Therapeutics. Author of Partnering for Growth.
[ Careers ]
Come build with us.
We're bringing together scientists and engineers who want to join our mission to bring more and better drugs into the world.
If you're deeply motivated by that mission, let's talk.
